A Case Report of Posttransplant Lymphoproliferative Disorder After AstraZeneca Coronavirus Disease 2019 Vaccine in a Heart Transplant Recipient

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

We report a case of a heart transplant recipient who presented with a rapidly growing Epstein-Barr virus (EBV)–positive, diffuse large B-cell lymphoma 7 days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. Because of the atypical radiologic presentation, the initial tentative diagnosis was a mediastinal abscess. This observation indicates a potential risk of EBV reactivation after coronavirus disease 2019 (COVID-19) vaccination, which might lead to or aggravate the presentation of posttransplant lymphoproliferative disorder in transplantation patients. Transplant surgeons should be aware of the potential immunomodulatory effects of the COVID-19 vaccination.

Original languageEnglish
Pages (from-to)1575-1578
Number of pages4
JournalTransplantation Proceedings
Volume54
Issue number6
DOIs
Publication statusPublished - 2022 Jul 1

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Fingerprint

Dive into the research topics of 'A Case Report of Posttransplant Lymphoproliferative Disorder After AstraZeneca Coronavirus Disease 2019 Vaccine in a Heart Transplant Recipient'. Together they form a unique fingerprint.

Cite this